IP Library Granted Patent US 8,821,457
Granted Patent B2
US 8,821,457 · App. 13/197,258 · Granted Sep 2, 2014

Punctal plug containing drug formulation

Inventors: Nathan R. F. Beeley (Santa Barbara, CA); Bret A. Coldren (Vista, CA); Victor Lust (Jacksonville, FL)
Assignee: Johnson & Johnson Vision Care, Inc.
A61F9/00772A61F9/0017A61K9/0051A61M31/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,821,457
App. No.
13/197,258
Granted
Sep 2, 2014
Kind
B2
Abstract

Disclosed are lacrimal inserts and their method of use for delivery of medication to the eye. The plug includes a body portion sized to pass through a lacrimal punctum and be positioned within a lacrimal canaliculus of the eyelid. The plug may contain a core, or reservoir, at least partially within the body portion comprising a therapeutic agent that is configured to controlled release into the eye and is configured for release medication via a designated port, valve, or orifice in the insert housing and inhibits diffusion of medication via the housing itself.

Claims (7)

1. A lacrimal insert, the lacrimal insert comprising:

a housing including a flange portion, a substantially cylindrical portion, and a diamond shaped cross-section portion, the housing also including at least one opening in fluid communication with a reservoir defined by the housing;

a drug core including one or more therapeutic agents, the drug core being positioned within the reservoir defined by the housing and comprising a substantially cylindrical portion and a diamond-shaped cross-section portion the drug core taking the shape of and filling the reservoir, and making contact with the housing, the substantially cylindrical portions of the housing and the drug core and the diamond shaped cross-section portions of the housing and the drug core being aligned with one another to form a complimentary fit to prevent movement of the drug core relative to the housing; and

a barrier layer affixed to at least one of the housing and the drug core, the barrier layer being configured to inhibit the diffusion of the therapeutic agent through the housing.

2. The lacrimal insert of claim 1 wherein the housing comprises a material selected the following: Polytetrafluoroethylene, Fluorinatedethylenepropylene, Perfluoroalkoxy, Polyvinylidene Fluoride, Tetrafluoroethylene, Hexafluoropropylene and Vinylidene Fluoride, Ethylenetetrafluoroethylene, Chloro Trifluoro Ethylene / Ethylene Copolymer, Polyethylene Terepthalate Polyester, Polyetheretherketone, Nylon 6/6, Nylon 11, Nylon 12, Pebax, Polyethylene, Ultra high molecular weight polyethylene, Ultra low molecular weight polyethylene, High molecular weight polyethylene, High density polyethylene, High density cross-linked polyethylene, Cross-linked polyethylene, Medium density polyethylene, Low density polyethylene, Linear low density polyethylene, Very low density polyethylene, Polypropylene, Polycaprolactone, Cellulose and cellulose derivatives, Cellulose Acetate, Polycarbonate, Cyanoacrylate, Eudragit, Polyimide, Polyamide, Ethylene Vinyl Acetate, Polyurethane, Polysulfone, Polyetherimide, Polytheresulfone, Styrene butadiene Rubber, Polyphenylene Sulfide, Polyphenylene Oxide, Ethylene Propylene Diene Monomer (Rubber), Zeonor, Zeonex, Parylene, Parylene N, Parylene C, Parylene D, Parylene AF-4, Parylene SF, Parylene HT, Parylene A, Parylene AM, Parylene VT-4, Parylene CF, and Parylene X, Polyvinyl alcohol, Polyvinyl acetate, Polyvinyl chloride, Polyisobutylene, Fluro silicones, Liquid curable perfluoropolyether, and Polystyrene.

3. The lacrimal insert of claim 1 wherein the barrier layer comprises a material selected from the following:

Polytetrafluoroethylene, Fluorinatedethylenepropylene, Perfluoroalkoxy, Polyvinylidene Fluoride, Tetrafluoroethylene, Hexafluoropropylene and Vinylidene Fluoride, Ethylenetetrafluoroethylene, Chloro Trifluoro Ethylene / Ethylene Copolymer, Polyethylene Terepthalate Polyester, Polyetheretherketone, Nylon 6/6, Nylon 11, Nylon 12, Pebax, Polyethylene, Ultra high molecular weight polyethylene, Ultra low molecular weight polyethylene, High molecular weight polyethylene, High density polyethylene, High density cross-linked polyethylene, Cross-linked polyethylene, Medium density polyethylene, Low density polyethylene, Linear low density polyethylene, Very low density polyethylene, Polypropylene, Polycaprolactone, Cellulose and cellulose derivatives, Cellulose Acetate, Polycarbonate, Cyanoacrylate, Eudragit, Polyimide, Polyamide, Ethylene Vinyl Acetate, Polyurethane, Polysulfone, Polyetherimide, Polytheresulfone, Styrene butadiene Rubber, Polyphenylene Sulfide, Polyphenylene Oxide, Ethylene Propylene Diene Monomer (Rubber), Zeonor, Zeonex, Parylene, Parylene N, Parylene C, Parylene D, Parylene AF-4, Parylene SF, Parylene HT, Parylene A, Parylene AM, Parylene VT-4, Parylene CF, and Parylene X, Polyvinyl alcohol, Polyvinyl acetate, Polyvinyl chloride, Polyisobutylene, Fluro silicones, Liquid curable perfluoropolyether, and Polystyrene.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2011
From: BEELEY, NATHAN R. F.; COLDREN, BRET A.; LUST, VICTOR
To: JOHNSON & JOHNSON VISION CARE, INC.
Reel/Frame 026694/0519 →
Continuity (2)
Provisional Application 61380737 · Sep 8, 2010
Related Publication 20120059338A1 · Mar 8, 2012